Boldine induces cell cycle arrest and apoptosis in T24 human bladder cancer cell line via regulation of ERK, AKT, and GSK-3β

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 36.e1-36.e9

  Gerhardt, Daniéli ^a   Bertola, Gabriela ^a   Dietrich, Fabrícia ^a   Figueiró, Fabrício ^a   Zanotto Filho, Alfeu ^a   Moreira Fonseca, José Cláudio ^a   Morrone, Fernanda Bueno ^b   Barrios, Carlos Henrique ^b   Battastini, Ana Maria O ^a   Salbego, Christianne G ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Apoptosis; Bladder cancer; Boldine; Cell signaling

Indexed keywords

5' NUCLEOTIDASE; BOLDINE; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SULFORHODAMINE B; TETRAZOLIUM; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; APORPHINE DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; LISSAMINE RHODAMINE B; PLANT EXTRACT; RHODAMINE; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; PEUMUS BOLDUS; PRIORITY JOURNAL; WESTERN BLOTTING; BLADDER TUMOR; CELL CYCLE CHECKPOINT; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APORPHINES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLYCOGEN SYNTHASE KINASE 3; HUMANS; PEUMUS; PLANT EXTRACTS; PROTO-ONCOGENE PROTEINS C-AKT; RHODAMINES; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES; URINARY BLADDER NEOPLASMS;

EID: 84890802667     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.02.012     Document Type: Article

References (45)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Ferlay J., Bray F., Pisani P., Parkin D.M. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide 2004, IARC Press, Lyon.
3. Parkin D.M. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 2008, 218:12-20.
4. Ploeg M., Aben K.K., Kiemeney L.A. The present and future burden of urinary bladder cancer in the world. World J. Urol 2009, 27:289-293.
5. Ismaili N., Amzerin M., Flechon A. Chemotherapy in advanced bladder cancer current status future. J Hematol Oncol 2011, 4:35.
6. Boyle H., Fléchon A., Droz J.P. Treatment of uncommon malignant tumours of the bladder. Curr Opin Urol 2011, 21:309-314.
7. Ismaili N., Arifi S., Flechon A., et al. Small cell cancer of the bladder: pathology, diagnosis, treatment and prognosis. Bull Cancer 2009, 96:E30-E44.
8. Kitamura H., Tsukamoto T. Early bladder cancer: concept, diagnosis, and management. Int J Clin Oncol 2006, 11:28-37.
9. Osterlink W. Guidelines on diagnosis and treatment of superficial bladder cancer. Minerva Urol Nefrol 2004, 56:65-72.
10. Tsukamoto T., Kitamura H., Takahashi A., Masumori N. Treatment of invasive bladder cancer. Lessons from the past and perspective for the future. Jpn J Clin Oncol 2004, 34:295-306.
11. Speisky H., Cassels B.K. Boldo and boldine: an emerging case of natural drug development. Pharmacol Res 1994, 29:1-12.
12. Bubeník J., Baresová M., Viklický V., Jakoubková J., Sainerová H., Donner J. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer 1973, 11:765-773.
13. Skehan P., Storeng R., Scudiero D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990, 82:1107-1112.
14. Overton W.R., McCoy J.P. Reversing the effect of formalin on the binding of propidium iodide to DNA. Cytometry 1994, 16:351-356.
15. Lin C., Lee C., Shih Y., et al. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic Biol Med 2012, 52:377-391.
16. 2+-ATPase activity. Anal Biochem 1986, 157:375-380.
17. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
18. Stella J., Bavaresco L., Braganhol E., et al. Differential ectonucleotidase expression in human bladder cancer cell lines. Urol Oncol 2010, 28:260-267.
19. Spychala J. Tumor-promoting functions of adenosine. Pharmacol Ther 2000, 87:161-173.
20. Wang L., Zhou X., Zhou T., et al. Ecto-5'-nucleotidase promotes invasion, migration, and adhesion of human breast cancer cells. J Cancer Res Clin Oncol 2006, 134:365-372.
21. Rockenbach L., Bavaresco L., Farias P., et al. Alterations in extracellular catabolism of nucleotides are involved in the antiproliferative effect of quercetin in human bladder cancer T24 cells. Urol Oncol 2011, [x:x-x].
22. Joshi A., Preslan E. Risk factors for bladder cancer: challenges of conducting a literature search using PubMed. Perspect Health Inf Manag 2011, 8:1e.
23. Hoet S., Stévigny C., Block S. Alkaloids from Cassytha filiformis and related aporphines: antitrypanosomal activity, cytotoxicity, and interaction with DNA and topoisomerases. Planta Med 2004, 70:407-413.
24. Gerhardt D., Horn A.P., Gaelzer M.M., et al. Boldine: a potencial new antiproliferative drug against glioma cell line. Invest New Drugs 2009, 27:517-525.
25. Williams G.H., Stoeber K. The cell cycle and cancer. J Pathol 2012, 226:352-364.
26. Zanotto Filho A., Braganhol E., Edelweiss M.I., et al. The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma. J Nutr Biochem 2012, 23:591-601.
27. Zanotto-Filho A., Delgado-Cañedo A., Schröder R., Becker M., Klamt F., Moreira J.C. The pharmacological NFkappaB inhibitors BAY117082 and MG132 induce cell arrest and apoptosis in leukemia cells through ROS-mitochondria pathway activation. Cancer Lett 2010, 288:192-203.
28. Ramos J.W. The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol 2008, 40:2707-2719.
29. Li C., Teng R.-H., Tsai Y.-C., et al. H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 blader carcinoma cells. Br J Cancer 2005, 92:80-88.
30. Yan J., Roy S., Apolloni A., et al. Ras isoforms vary in their ability to activate Raf-1 and Phosphoinositide 3-kinase. JBC 1998, 37:24052-24056.
31. Steelman L.S., Chappell W.H., Abrams S.L. Roles of the Raf/MEK/ERK and PI3K/PTEN/AKT/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging 2011, 3:192-222.
32. McCubrey J.A., Ls Steelman, Chappell W.H. Roles of the RAF/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007, 1773:1263-1284.
33. Chambard J.C., Lefloch R., Pouysségur J., Lenormand P. ERK implication in cell cycle regulation. Biochim Biophys Acta 2007, 1773:1299-1310.
34. Sebolt-Leopold J.S., Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004, 4:937-947.
35. Johnstone R., Ruefli A., Lowe S. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108:153-164.
36. Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995, 184:39-51.
37. Wu X., Obata T., Khan Q., et al. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 2004, 93:143-150.
38. Widelitz R. Wnt signaling through canonical and non-canonical pathways: recent progress. Growth Factors 2005, 23:111-116.
39. Cheng J.Q., Lindsley C.W., Cheng G.Z., Yang H., Nicosia S.V. The AKT/PKB pathway: molecular target for cancer drug discovery. Oncogene 2005, 24:7482-7492.
40. Wu D., Tao J., Xu B., et al. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells. Urol Int 2011, 87:105-113.
41. Wallerand H., Reiter R.R., Ravaud A. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signaling pathways. Curr Opin Urol 2008, 18:524-532.
42. Wilhelm S., Chien D.S. BAY 43-9006: preclinical data. Curr Pharm Des 2001, 8:2255-2257.
43. Liu H., Zang C., Schefe J.H. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro. Anticancer Res 2011, 31:2713-2722.
44. Boulalas I., Zaravinos A., Karyotis I., Delakas D., Spandidos D.A. Activation of RAS family genes in urothelial carcinoma. J Urol 2009, 181:2312-2319.
45. Bartholomeusz C., Gonzalez-Angulo A.M. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 2012, 16:121-130.